Profound Medical (NASDAQ:PROF – Get Rating) had its price target lifted by investment analysts at Raymond James from $15.00 to $17.00 in a research note issued to investors on Wednesday, BayStreet.CA reports. The firm presently has a “strong-buy” rating on the stock. Raymond James’ price target points to a potential upside of 61.75% from the company’s previous close.
Separately, Lake Street Capital upped their target price on shares of Profound Medical from $7.00 to $14.00 in a research note on Friday, January 6th.
Profound Medical Stock Performance
PROF stock opened at $10.51 on Wednesday. The company’s 50 day moving average price is $12.13 and its 200 day moving average price is $7.80. Profound Medical has a fifty-two week low of $3.10 and a fifty-two week high of $13.52. The firm has a market capitalization of $219.45 million, a price-to-earnings ratio of -7.62 and a beta of 0.84.
Institutional Trading of Profound Medical
Profound Medical Company Profile
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The firm’s platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy.
- Get a free copy of the StockNews.com research report on Profound Medical (PROF)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.